🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Global Challenge

Gonorrhoea infections are escalating around the world, with data suggesting over 82 million instances per year. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, gained clearance in the same week. This medication, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

According to results published in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The trial included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in many developing nations.

Medical professionals treating patients have shared positive views. The availability of a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed vital to lessen the impact of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.